Clinical Trials Sponsored by Matinas BioPharma Nanotechnologies, Inc.

Total 11 results

Matinas BioPharma Nanotechnologies, Inc.

Completed

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Vulvovaginitis | Candidiasis, Vulvovaginal | Yeast Infection | Yeast Infection Vaginal

United States
Matinas BioPharma Nanotechnologies, Inc.

Withdrawn

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

Vulvovaginitis | Candidiasis, Vulvovaginal | Vulvovaginal Candidiases | Yeast Infection | Yeast Infection Vaginal

United States
Matinas BioPharma Nanotechnologies, Inc.

Completed

CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis (CAMB)

Candidiasis, Chronic Mucocutaneous

United States
Matinas BioPharma Nanotechnologies, Inc.
University of Minnesota

Not yet recruiting

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 (EnACT3)

Cryptococcal Meningitis
Matinas BioPharma Nanotechnologies, Inc.
University of Minnesota

Completed

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) (EnACT)

Cryptococcal Meningitis

Uganda
Matinas BioPharma Nanotechnologies, Inc.
University of Minnesota

Withdrawn

Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection (ORACLE)

Cryptococcal Infections
Matinas BioPharma Nanotechnologies, Inc.
MB Clinical Research and Consulting LLC; Matinas Biopharma, Inc

Completed

Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (ENHANCE-IT)

Hypertriglyceridemia

United States
Matinas Biopharma, Inc

Completed

A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules (PK/PD)

Hypertriglyceridemia

Canada
Matinas BioPharma Nanotechnologies, Inc.
University of Cologne; The Clinical Trials Centre Cologne

Withdrawn

Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia
Matinas Biopharma, Inc
Covance

Withdrawn

Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL (AMPLIFY)

Severe Hypertriglyceridemia
University of Cologne
Pfizer; F2G Biotech GmbH; Basilea Pharmaceutica; Cidara Therapeutics Inc.; Matinas...

Recruiting

FungiScope - A Global Emerging Fungal Infection Registry (FungiScope)

Invasive Fungal Disease

Germany

Clinical Trials Sponsored by Matinas BioPharma Nanotechnologies, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations